Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) has earned an average rating of “Hold” from the twenty-one ratings firms that are presently covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and nine have issued a buy rating on the company. The average 1 year target price among brokers that have covered the stock in the last year is $53.42.

PCRX has been the topic of several recent research reports. Canaccord Genuity reduced their price target on Pacira Pharmaceuticals from $56.00 to $48.00 and set a “buy” rating on the stock in a research note on Tuesday, August 29th. CIBC initiated coverage on Pacira Pharmaceuticals in a research note on Thursday, September 7th. They issued a “market perform” rating on the stock. Mizuho reaffirmed a “buy” rating and issued a $54.00 price target on shares of Pacira Pharmaceuticals in a research note on Wednesday, July 26th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $59.00 price target on shares of Pacira Pharmaceuticals in a research note on Thursday, September 7th. Finally, Royal Bank Of Canada set a $58.00 price target on Pacira Pharmaceuticals and gave the stock a “buy” rating in a research note on Sunday, July 30th.

Pacira Pharmaceuticals (PCRX) opened at 37.05 on Friday. Pacira Pharmaceuticals has a one year low of $29.95 and a one year high of $58.95. The company has a 50 day moving average price of $37.12 and a 200-day moving average price of $44.48. The company’s market capitalization is $1.49 billion.

Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its quarterly earnings results on Wednesday, August 2nd. The company reported ($0.11) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by ($0.06). The firm had revenue of $70.90 million during the quarter, compared to analysts’ expectations of $73.37 million. Pacira Pharmaceuticals had a negative return on equity of 12.44% and a negative net margin of 23.36%. Pacira Pharmaceuticals’s revenue for the quarter was up 1.9% on a year-over-year basis. During the same period in the previous year, the company earned $0.21 earnings per share. Analysts expect that Pacira Pharmaceuticals will post ($0.17) EPS for the current fiscal year.

In other news, CAO Kristen Marie Williams sold 3,461 shares of the company’s stock in a transaction on Tuesday, August 15th. The stock was sold at an average price of $36.75, for a total transaction of $127,191.75. Following the transaction, the chief accounting officer now directly owns 21,312 shares of the company’s stock, valued at $783,216. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Paul J. Hastings sold 1,044 shares of the company’s stock in a transaction on Tuesday, August 22nd. The shares were sold at an average price of $36.15, for a total value of $37,740.60. Following the transaction, the director now directly owns 3,518 shares in the company, valued at $127,175.70. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 33,390 shares of company stock worth $1,215,480. Corporate insiders own 6.60% of the company’s stock.

A number of hedge funds have recently bought and sold shares of PCRX. Teachers Advisors LLC lifted its holdings in Pacira Pharmaceuticals by 6.2% in the fourth quarter. Teachers Advisors LLC now owns 62,854 shares of the company’s stock valued at $2,030,000 after acquiring an additional 3,658 shares during the period. Nationwide Fund Advisors lifted its holdings in Pacira Pharmaceuticals by 147.4% in the first quarter. Nationwide Fund Advisors now owns 56,190 shares of the company’s stock valued at $2,562,000 after acquiring an additional 33,482 shares during the period. Capital Fund Management S.A. bought a new position in Pacira Pharmaceuticals in the first quarter valued at about $300,000. US Bancorp DE lifted its holdings in Pacira Pharmaceuticals by 50.5% in the first quarter. US Bancorp DE now owns 8,989 shares of the company’s stock valued at $410,000 after acquiring an additional 3,015 shares during the period. Finally, Bank of New York Mellon Corp lifted its holdings in Pacira Pharmaceuticals by 4.2% in the first quarter. Bank of New York Mellon Corp now owns 206,435 shares of the company’s stock valued at $9,415,000 after acquiring an additional 8,366 shares during the period.

ILLEGAL ACTIVITY NOTICE: This news story was posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/09/16/pacira-pharmaceuticals-inc-pcrx-receives-consensus-rating-of-hold-from-brokerages.html.

Pacira Pharmaceuticals Company Profile

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Analyst Recommendations for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.